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Background: Plasmodium knowlesi is the fifth species identified to cause malaria in humans and is often
misdiagnosed as Plasmodium malariae due to morphological similarities. The development of an inexpensive,
serological detection method utilizing antibodies specific to P. knowlesi would be a valuable tool for diagnosis.
However, the identification of specific antigens for these parasites remains a major challenge for generating such
assays. In this study, surface protein containing an altered thrombospondin repeat domain (SPATR) was selected as
a potentially specific antigen from P. knowlesi. Its multistage expression by sporozoites, asexual erythrocytic forms
and gametocytes, along with its possible role in liver cell invasion, suggests that SPATR could be used as a
biomarker for diagnosis of P. knowlesi.
Methods: The spatr gene from P. knowlesi was codon optimized and cloned (pkhspatr). Recombinant pkHSPATR
protein was expressed, purified, and evaluated for its sensitivity and specificity in immunoblot and ELISA-based
assays for detecting P. knowlesi infection.
Results: The recombinant pkHSPATR protein allows sensitive detection of human P. knowlesi infection in serum
samples by immunoblot and ELISA.
Conclusions: With further research, recombinant pkHSPATR protein could be exploited as a marker for detection of
P. knowlesi infection in humans. Therefore, this finding should contribute to the development of immunodiagnostic
assays for the species-specific detection of malaria.
Keywords: Malaria, Detection, Plasmodium knowlesi, ELISA, Surface protein containing an altered thrombospondin
repeat domain (SPATR)Background
Malaria remains a major health threat in many parts of
the world. In 2012, the World Malaria Report by the
World Health Organization (WHO) reported an esti-
mated 219 million cases of malaria and 660,000 deaths
for the year 2010. Emergence of Plasmodium knowlesi as
the fifth human malaria species has raised the concern of
scientists on the prospect for malaria elimination [1].
The P. knowlesi parasites have a 24-hour life cycle, which
results in rapid amplification of parasitaemia. P. knowlesi* Correspondence: lauyeeling@um.edu.my
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reproduction in any medium, provided the orinfection is fast spreading and potentially dangerous,
which makes accurate diagnosis vital for effective treat-
ment of this parasitic disease. However, P. knowlesi para-
sites are often misdiagnosed as Plasmodium malariae
due to their morphological similarities [2]. Use of poly-
merase chain reaction (PCR) to detect P. knowlesi infec-
tion is also not very accurate as the species-specific
primers have been reported to crossreact with Plasmo-
dium vivax [3] due to the close phylogenetic relationship
of these two species. Thus, the development of an inex-
pensive, serological detection method utilizing antibodies
specific to P. knowlesi would be a valuable tool for diag-
nosis of knowlesi malaria. Increased understanding onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malarial genes, due to recent advances in bio-informatics
has been very helpful in evaluating new antigens as
potential diagnostic or vaccine candidates.
The phylum Apicomplexa comprises a large group of
protists, including Babesia, Plasmodium, Cryptosporidium
and Toxoplasma, which are characterized by specialized
secretory organelles found at their apical prominence.
These apical structures, consisting of micronemes,
rhoptries, and dense granules [4], contain many proteins
that are involved in parasite motility and host cell inva-
sion. Many invasive stages of Plasmodium have been
found to contain one or more thrombospondin type-1
repeat (TSR) domain [5], suggesting the possible role of
this domain in sporozoite motility and hepatocyte inva-
sion. An altered version of the thrombospondin repeat do-
main was first found in Plasmodium yoelii [6,7] and
named the surface protein of altered thrombospondin re-
peat (SPATR). Orthologue of this protein has also been
identified in P. knowlesi and named the pkSPATR.
SPATR protein is expressed during many stages of the
P. knowlesi life cycle, including the sporozoite, merozoite
and gametocyte stages [6]. Importantly, it is expressed
on the cell surface during the sporozoite stage, where it
is involved in liver cell invasion. In fact, it was previously
demonstrated that recombinant SPATR from Plasmo-
dium falciparum and its orthologue in P. knowlesi were
able to bind to HepG2 cells with high specificity, and
antibodies generated against SPATR could inhibit P. fal-
ciparum sporozoite invasion into liver cells [6,7]. The P.
falciparum SPATR protein was recognized by sera from
naturally infected Africans but not control sera from
two non-immune donors, indicating that this protein
was recognized by the host immune system [6].
In this study, the P. knowlesi spatr gene sequence was
codon optimized and cloned (pkhspatr). Moreover, recom-
binant pkHSPATR protein was expressed, purified, and
evaluated for its sensitivity and specificity in immunoblot-
and ELISA-based assays for detecting P. knowlesi infection
in human serum samples.
Methods
Polymerase chain reaction (PCR) and cloning
The P. knowlesi spatr gene sequence was identified in
a BLAST search of the P. knowlesi database using the
published sequence of P. falciparum spatr [GenBank:
AY952327] as a query sequence. The spatr sequence was
codon optimized by Epoch Life Science Inc (USA) in
order to enhance expression in Escherichia coli. The syn-
thetic gene (806 base pairs, full length) was designated as
pkhspatr and was cloned into SmaI digested pBluescript II
SK. Forward (5′-GAATTCAAAA GAATGAAGAAG-3′)
and reverse (5′-GAATTCGCCGTTTTGGTTAGTAG-3′)
primers were used to PCR amplify pkhspatr, which wasthen cloned into pGEM-T vector (Invitrogen, USA). EcoRI
restriction sites were introduced into both the forward
and reverse primers in order to facilitate cloning. The
pkhspatr gene was then digested with EcoRI restriction
enzyme and cloned into the T7 promoter-based pRSET
B vector, which allows expression of dually polyhistidine
(His)- and Xpress epitope-tagged (both at the N-terminus)
recombinant proteins in E. coli (Invitrogen, USA). The
nucleotide sequence was analysed by NHK Bioscience
Solutions Sdn Bhd (Malaysia).
Expression of recombinant pkHSPATR
For protein expression in E. coli, the pkhspatr-pRSET B
recombinant plasmid was transformed into Rosetta DE3
competent cells (Novagen, USA). Transformants were
plated onto Luria-Bertani (LB) agar plates, which were
supplemented with ampicillin (100 μg/ml) and chloram-
phenicol (32 μg/ml). A single, positive transformed colony
was inoculated for expression of recombinant SPATR pro-
tein. After the culture reached an optical density at 600
nm of 0.6, expression of the pkhspatr gene was induced
with 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG)
for four hours. Cells were then pelleted at 5,000 rpm for
10 min, the supernatant was discarded, and the wet weight
of the pellet was determined. The pellet was then
resuspended in 5 ml of Bug Buster reagent (Novagen,
USA) per gram of wet pellet, and 1 μl of Benzonase
(50 mM Tris-HCl, pH 8.0, 20 mM NaCl, and 2 mM
MgCl2 in 50% glycerol) was added per ml of Bug Buster
reagent used. Insoluble cell debris were separated through
centrifugation at 16,000 x g for 20 min at 4°C, and the pel-
let was further lysed using 200 μg/ml lysozyme in the
same volume of Bug Buster reagent that had been used
during pellet resuspension. The cell suspension was then
centrifuged at 16,000 × g for 15 min at 4°C, and the
resulting pellet was repeatedly washed with 1:10 diluted
Bug Buster reagent. After three washes, the final inclusion
body-containing pellet was resuspended in phosphate
buffered saline (PBS), and a small fraction was saved for
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blot analysis.
Purification of recombinant pkHSPATR
Recombinant pkHSPATR protein was resuspended in 8 ml
of 6 M urea and added to a ProBond column (Invitrogen,
USA). The column was placed on a MACSmix™ Tube
Rotator (Miltenyi Biotec, Germany), and the His-tagged
protein was allowed to bind to the Ni-NTA agarose for
four hours at 4°C. Once the resin had settled, the super-
natant was gently aspirated, and the column was washed
with 8 ml of 6 M urea. This step was repeated with 4 M
and 2 M urea. Finally the protein was eluted with 1 ml of
1 M urea and 250 mM imidazole. The purity of recombin-
ant pkHSPATR was determined using a 12% SDS-PAGE
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overnight at 4°C with two buffer changes during the dialy-
sis period. The final purified pkHSPATR protein was
quantified using the Bradford Assay Kit (Bio-Rad, USA).
Gel electrophoresis and western blot
Proteins were separated according to their molecular
weight using a 12% SDS-PAGE gel and transferred by
electroblotting onto a polyvinylidene difluoride (PVDF)
membrane (Bio-Rad, USA). The membranes were blocked
overnight at 4°C using blocking solution (5% [w/v] skim
milk in 1X Tris-buffered saline [TBS]). They were then
washed twice using 1X TBS with 0.01% Tween 20 (TBST),
followed by two washes with 1X TBS. After incubation
with primary antibody (anti-Xpress antibody, 1:5,000 dilu-
tion, Invitrogen, USA; or human serum, 1:200 dilution) in
TBS with 2.5% (w/v) skim milk at room temperature
for two hours, the membrane was washed twice with both
TBST and TBS. Bound antibodies were incubated
with secondary antibody, biotin-labelled goat anti-mouse
IgG (for anti-Xpress antibody) or biotin- labelled goat
anti-human IgG (for human serum) (1:2,500 dilution)
(Kirkegaard and Perry Laboratories, USA). This step was
followed by incubation for an hour at room temperature
with streptavidin–alkaline phosphatase (AP) (1:2,500 dilu-
tion) (Invitrogen, USA) and the standard washing step.
Protein band was visualized using 5-bromo-4-chloro-3-
indolyl phosphate and nitroblue tetrazolium (Sigma
Chemical Co, USA).
ELISA
A 96-well ELISA plate was coated with 10 μg of pkHSPATR
recombinant protein and incubated overnight at 4°C. The
next day, the plate was washed three times using PBS with
0.01% Tween 20 (PBST) and blocked with 1% BSA (Bovine
Serum Albumin) in PBS for two hours at 37°C. Following
three washes with PBST, the plate was incubated with pa-
tient serum (1:80 dilution) for one hour at 37°C, washed
five times with PBST, and incubated with HRP-conjugated
goat anti-human lgG (1:2,500 dilution) at 37°C for one
hour. The plate was then washed vigorously with PBST
(five times), and 3,3′,5,5′-tetramethylbenzidine (TMB) was
used for the development reaction (20 min incubation in
the dark). Optical density was read at 450 nm using an
Infinite 200 PRO plate reader (TECAN, Switzerland).
Sensitivity and specificity evaluation of recombinant
pkHSPATR
Purified recombinant protein was further evaluated
through western blot and ELISA using human serum
samples obtained from Diagnostic Laboratory (Para:
SEAD), Department of Parasitology, University of
Malaya. The serum samples were categorized into four
groups according to previous diagnosis using PCR andmicroscopy: (i) P. knowlesi; (ii) non-knowlesi Plasmodium;
(iii) healthy donors (88 samples); and (iv) non-malaria
parasitic infections, including Toxoplasma gondii (14 sam-
ples), amoebiasis (three samples), cysticercosis (two sam-
ples), and filariasis (two samples). In addition, 11 malaria
negative samples, which were initially suspected as malaria
infection, were included within the other infections group.
The cut-off value for ELISA was calculated based on the
healthy donor samples (mean + 2SD).Results
PCR and cloning
The codon optimized pkhspatr gene was successfully amp-
lified (806 bp) and cloned into the pRSET B vector, which
allows bacterial expression of dually His- and Xpress
epitope-tagged recombinant proteins. The pkhspatr-pRSET
B plasmid was then isolated and sequenced. Sequence ana-
lysis indicated a complete match with the published amino
acid sequence of Mahajan [6]. The plasmid was then
transformed into Rosetta DE3 competent E. coli cells.
Expression of recombinant pkHSPATR
Recombinant pkHSPATR protein expression was induced
using 1 mM IPTG. The protein was expressed four hours
after induction and was visible on a 12% Coomassie blue-
stained polyacrylamide gel as a 32 kDa band, which was
not observed in the negative control (Figure 1). The re-
combinant pkHSPATR was predominantly found within
aggregated inclusion bodies. Initially, the cell culture pellet
formed a viscous solution when resuspended in PBS and
formed insoluble precipitates when boiled with equal vol-
ume of 2X loading dye (100 mM Tris-HCL, 4% SDS, 0.2%
bromophenol blue, 20% glycerol, 2.5% mercaptoethanol).
The recombinant protein was recovered from inclusion
bodies by using the Bug Buster protein extraction kit.
Also, Benzonase was added to release the target protein
and to reduce the viscosity of the extract.
Purification of recombinant pkHSPATR
Recombinant pkHSPATR was successfully purified under
denaturing conditions using Ni-NTA column. The puri-
fied protein was run on 12% polyacrylamide gels, and both
Coomassie staining and western blot with anti-Xpress re-
vealed a single band at the expected molecular mass of
32 kDa (Figures 2 and 3). Quantification of pkHSPATR
using Bradford assay yielded a protein concentration of
0.2-0.4 mg/ml.
Evaluation of sensitivity and specificity of recombinant
pkHSPATR in detection assays
The sensitivity and specificity of purified pkHSPATR for
detection of P. knowlesi was evaluated using western blot
and ELISA. Human serum samples from four groups were
Figure 1 SDS-PAGE analysis on expression of recombinant
pkHSPATR protein at fourth hour of induction. Lane 1-3, Bug
Buster extraction of pRSET-B vector protein (control); lane 4-5, Bug
Buster extraction of pkHSPATR protein; pkHSPATR protein without
Bug Buster extraction. Arrow indicates expression of pkHSPATR
protein at expected size (32 kDa).
Figure 2 SDS-PAGE analysis of Ni-NTA purified recombinant
pkHSPATR protein and vector control. Lane 1, unbound protein
(aspirated supernatant after binding); Lane 2-3, first and second
eluate after purification; lane 4, pRSET-B vector protein
after purification.
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(iii) healthy donors (88 samples); and (iv) non-malaria
parasitic infections, including T. gondii (14 samples),
amoebiasis (three samples), cysticercosis (two samples),
and filariasis (two samples). In the western blot assay, 38
out of 40 (95.0%) of the P. knowlesi-infected serum sam-
ples reacted with the recombinant pkHSPATR, yielding a
band at ~32 kDa. The two samples not detected by west-
ern blot assay were presented with very low parasitemia
level, undetectable under microscopy and PCR demon-
strated faint bands upon electrophoresis. For non-knowlesi
Plasmodium samples, five out of 31 (16.1%) of the samples
gave a faint positive band. Of these, two samples were
from P. falciparum infections, while the rest were from
P. vivax infections. None of the non-malaria and healthy
donor serum samples detected a band in the western blot
assay (Figure 4). As for ELISA, 35 out of 40 (87.5%) of the
P. knowlesi samples reacted with pkHSPATR, while six out
of 31 (19.4%) of the non-knowlesi Plasmodium samples
reacted with the recombinant protein. No samples from
the other infections reacted with the recombinant protein.
Finally, the sensitivity (number of true positives/number
of true positives + number of false negatives) and the
specificity (number of true negatives/number of true nega-
tives + number of false positives) of the pkHSPATR-based
assays were determined. The calculated values for sensitiv-
ity and specificity of pkHSPATR in the western blot assay
were 95 and 96.7%, respectively. Sensitivity and specificity
of pkHSPATR in the ELISA-based assay were found to be
87.5 and 96.0%, respectively.Discussion
The complex malaria parasite life cycle, which is accom-
panied by alterations in gene expression at each of its
stages, results in major antigenic changes during malaria
infection [8]. Logically, the most reliable and effective anti-
gens for diagnosis of P. knowlesi infection would be those
that are expressed at multiple stages of the parasite
developement and preferably associated with invasion, se-
questration, and progression of pathogenesis in the host
[6]. In this regard, the multistage expressed spatr gene of
Plasmodium contains an altered TSR domain, which has
been reported to play a role in parasite mobility, host cell
attachment, and host cell invasion [5,6].
Here, cloning and expression of the spatr gene from P.
knowlesi were reported. Moreover, the recombinant
pkHSPATR protein was purified and tested if it can be uti-
lized to sensitively and specifically detect P. knowlesi infec-
tion in serum from malaria-infected individuals. In
addition, the native spatr gene fragment was codon
optimized to increase its expression level in E. coli. Gener-
ally, Plasmodium species have higher adenine and thymine
(A+T) content in their nucleotide sequences [9,10]. Thus,
Figure 3 Immunoblot analysis of Ni-NTA purified recombinant
pkHSPATR protein and vector protein (control). Lane 1, pRSET-B
vector protein (control) after purification; recombinant pkHSPATR
protein after purification.
Palaeya et al. Malaria Journal 2013, 12:182 Page 5 of 7
http://www.malariajournal.com/content/12/1/182codon bias of the Plasmodium gene within the heterol-
ogous expression system could interfere with successful
recombinant protein expression due to depletion of rare
transfer RNAs. Moreover, global reduction of A+T con-
tent can cause mRNA instability, or decrease the rate at
which the mRNA is exported into the cytoplasm
[10-12]. Nevertheless, using the codon optimized ver-
sion of the P. knowlesi pkhspatr gene, efficient expres-
sion was observed within E. coli system, allowing
successful purification of the pkHSPATR recombinant
protein.
The pkHSPATR recombinant protein was recovered
as inclusion bodies from the E. coli expression system.
The mechanism of inclusion body formation is still not
very well understood; however, polypeptide misfolding
caused by incorrect disulphide linkage among the
12 cysteine residues within the SPATR protein has
been proposed as one of the causes of inclusion body
formation [6]. In addition, temperature and pH of the
cultivation medium have been suggested as possible
contributing factors. Also, it has been hypothesized that
inclusion body formation might even stabilize the pro-
tein by protecting it from protease degradation. These
protein aggregates were once considered to be waste
products, but recent discoveries have revealed that in-
clusion bodies actually contain biologically active poly-
peptides [13]. The inclusion bodies purified in this
study were denatured using the Bug Buster protein ex-
traction kit, and sequential reduction in urea concentra-
tion was used to refold the denatured protein [14].
In a previous study, pooled sera from P. knowlesi-infected
rhesus monkeys were shown to react with recombinant
pkSPATR protein in ELISA [6]. This finding was extended
by systematically testing the sensitivity and specificity of the
use of pkHSPATR in two detection assays. In fact, the sensi-
tivity of recombinant pkHSPATR was differed between
western blot and ELISA for detecting antibodies against P.
knowlesi. In the ELISA assay, the cut-off value was based
on an average obtained from sera of healthy donors. How-
ever, it is possible that the empirically determined threshold
value may have been too high, causing P. knowlesi-infected
samples that had tested positive by western blot to be
considered negative in the ELISA. Moreover, the purity of
the recombinant protein might influence the readings
obtained in the ELISA, generating false positive results
[15,16] for non-knowlesi samples. Additionally, ELISA
could also underestimate the amount of bound recombin-
ant protein, as only the correctly folded protein might be
correctly detected, resulting in reduced sensitivity (Table 1).
Figure 4 Detection of recombinant pkHSPATR with patient sera infected by Plasmodium knowlesi and other parasite species. Each
western blot strip which contained the purified recombinant pkHSPATR was tested with serum from each category. Selected samples from each
category are shown. Lane M, Bio-Rad Prestained Broad Range Protein Marker; lanes 1 to 7, sera of patients infected with P. knowlesi; lane 8-10, serum of
patient infected with P. falciparum; lane 11-13, serum of patient infected with P. vivax; lanes 14-18, sera of patients infected with non-malarial parasites
(14- filariasis, 15- amoebiasis, 16- toxoplasmosis, 17- cysticercosis, 18- others), lane 19, healthy donor serum which served as negative control.
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trophoresis process denatures the protein, which allows
a more sensitive binding of P. knowlesi antibodies to
linear epitopes.
Cross-reactivity of the recombinant protein with
serum from individuals infected with other PlasmodiumTable 1 Sensitivity and specificity analysis of
recombinant pkHSPATR protein against human serum




of sera Western blot Elisa
Tested
Positive Negative Positive Negative
No. No. No. No.
A.Plasmodium
knowlesi
40 38 2 35 5
B.Non-knowlesi
Plasmodium
i.P.vivax 16 3 13 3 13
ii.P.falciparum 15 2 13 3 12
iii.P.ovale 1 0 1 0 1
C.Non-malaria parasitic
infection
i.Filariasis 2 0 2 0 2
ii.Amoebiasis 3 0 3 0 3
iii.Cysticercrosis 2 0 2 0 2
iv.Toxoplasmosis 14 0 14 0 14
v.Others* 11 0 11 0 11
Healthy donors 88 0 88 0 88
*Non-malaria patient presented with fever.species could result from shared sequence homology.
Antibodies directed against a specific protein often
interact with other closely related proteins with equal
specificity. In this regard, there is a conservation in the
number and position of all cysteine residues within the
SPATR proteins from P. knowlesi, P. falciparum,
P. vivax and P. yoelii [6]. Also, this similarity might be
consistent with previous studies of cysteine-rich malar-
ial proteins, which suggested that they were important
for parasite attachment and invasion of host cells. In-
deed, SPATR protein has been reported to attach to
human liver cells and play a role in hepatocyte invasion
by sporozoites.
Conclusions
In summary, the pkHSPATR recombinant protein seems
to allow sensitive detection of human P. knowlesi infec-
tion in serum samples by immunoblot and ELISA. With
further research, the pkHSPATR protein could be
exploited as a sensitive marker for detection of P.
knowlesi infection in humans; however, this protein re-
mains to be fully immunocharacterized. In addition,
findings from this study provide rationale for the pro-
duction of a specific recombinant antigen for use in
immunodiagnostic assays and P. knowlesi vaccine
development.
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